Clinical treatment strategy of Tis and T1 esophageal squamous cell carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053603

Enrollment

Unknown

Registered

2021-11-24

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal carcinoma

Interventions

Tis and T1a-m1, T1a-m2 control group:ESD

Tis and T1a-m1, T1a-m2 research group:Lymph node dissection + ESD/radical operation

T1a-m3, T1b-sm1 control group:ESD

T1a-m3, T1b-sm1 research group:Lymph node dissection + ESD/radical operation

T1a-sm2, T1b-sm3 control group:Radical operation

T1a-sm2, T1b-sm3 research group:Lymph node dissection + ESD+adjuvant therapy with radiotherapy and chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 70 years, can tolerate routine digestive endoscopy, imaging, biochemistry and endoscopic or surgical treatment; 2.Patients with high-grade intraepithelial neoplasia or esophageal squamous cell carcinoma within T1 diagnosed by endoscopy and pathology; 3.Patients who have good compliance and can cooperate to complete the whole clinical trial; 5.The subjects voluntarily participate in the test, and the subjects or their legal representatives can sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Lymph node or other organ metastasis was confirmed before operation; 2.Other conditions that will affect the survival and prognosis of patients include severe heart, kidney, liver diseases and malignant tumor diseases; 3.The patient voluntarily quits halfway; 4.Patients who without legal capacity, or medical or ethical condition affect the continuation of the research; 5.Preoperative radiotherapy and chemotherapy were performed.

Design outcomes

Primary

Measure	Time frame
Survival time;Relapse free survival;	—

Secondary

Measure	Time frame
Rapid pathological information of lymph nodes during operation;Intraoperative and postoperative complications;Operative information;Pathological information;Additional treatment after surgery;Imaging information;Tumor markers;Blood routine;Biochemical examination of blood;Metastatic melanoma of lymph nodes;	—

Countries

China

Contacts

Public ContactLin Rong; Liao Yongde

Union Hospital, Huazhong University of Science and Technology, Tongji Medical School

selinalin35@hotmail.com+86 15629180035; +86 15972212919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 11, 2026